Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.54 |
| ▸ | DDAH1 | O94760 | 4/20 | 0.50 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS1 | P29475 | 6/20 | 0.49 |
| ▸ | NOS3 | P29474 | 5/20 | 0.49 |
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ARG2 | P78540 | 4/20 | 0.43 |
| ▸ | ARG1 | P05089 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL4331631 | 1.00 | OTC (0.54) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL16486916 | 0.98 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL423342 | 0.98 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL28165841 | 0.98 | OTC (0.53) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL288132 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL1790 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL2411547 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL7928810 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL6374054 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 | |
| Arginine SCHEMBL31663499 | 0.98 | OTC (0.56) | OTCDDAH1NOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112251475-B | Method for improving L-glutamine fermentation yield and sugar-acid conversion rate | 乐康珍泰（天津）生物技术有限公司 | 2022-09-13 | — | — | CN | claimed |
| CN-112094873-A | Method for improving fermentation yield of L-isoleucine | 乐康珍泰（天津）生物技术有限公司 | 2020-12-18 | — | — | CN | claimed |
| EP-0928184-B1 | ANTI-CARIES ORAL COMPOSITIONS | UNIV NEW YORK STATE RES FOUND (US) | 2009-06-03 | — | — | EP | claimed |
| CN-1327472-A | Process for the transesterification of fats and/or oils of biological origin by means of alcoholysis | PETER SIEGFRIED (DE) | 2001-12-19 | — | — | CN | claimed |
| US-20250222111-A1 | DUAL-RATE RELEASE FORMULATION WITH HIGH DRUG LOADING | MATRIPHARM INT INC (CA) | 2025-07-10 | — | — | US | disclosed |
| CN-118717952-A | Composition for increasing bone mineral density and application thereof | 厦门中美康泰生物技术有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-117561065-A | Application of phylloic acid derivative in preparation of medicine for treating discomfort of contact lens and xerophthalmia | 连云港金康和信药业有限公司 | 2024-02-13 | — | — | CN | disclosed |
| WO-2022268167-A1 | APPLICATION OF FOLIC ACID DERIVATIVES IN PREPARATION OF DRUGS FOR TREATING CONTACT LENS DISCOMFORT AND XEROPHTHALMIA | 连云港金康和信药业有限公司 | 2022-12-29 | — | — | WO | disclosed |
| CN-112251475-B | Method for improving L-glutamine fermentation yield and sugar-acid conversion rate | 乐康珍泰（天津）生物技术有限公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20220111057-A1 | DUAL-RATE RELEASE FORMULATION WITH HIGH DRUG LOADING | MATRIPHARM INTERNATIONAL INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| CN-109294114-B | Arginine metal complex, compound heat stabilizer and application thereof | 浙江工业大学 | 2021-03-09 | — | — | CN | disclosed |
| CN-112094873-B | Method for improving fermentation yield of L-isoleucine | 乐康珍泰（天津）生物技术有限公司 | 2021-02-02 | — | — | CN | disclosed |
| EP-0928184-B1 | ANTI-CARIES ORAL COMPOSITIONS | UNIV NEW YORK STATE RES FOUND (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080286216-A1 | Surface Active Calcium Phosphates | KANNAR DAVID | 2008-11-20 | — | — | US | disclosed |
| CN-101218036-A | Content discharge mechanism, and aerosol-type product and pump-type product with the same | MITANI VALVE CO LTD (JP) | 2008-07-09 | — | — | CN | disclosed |
| CN-1666980-A | L-chelated calcium arginine | SHANGHAI FIRST HEALTH PRODUCTS (CN) | 2005-09-14 | — | — | CN | disclosed |
| US-6217851-B1 | MIXTURE OF CALCIUM, ARGININE AND BICARBONATE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK | 2001-04-17 | — | — | US | disclosed |
| EP-0928184-A1 | ANTI-CARIES ORAL COMPOSITIONS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1999-07-14 | — | — | EP | disclosed |
| US-5762911-A | CALCIUM CARBONATE, ARGININE, AND PHYTATE | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1998-06-09 | — | — | US | disclosed |
| WO-1997032565-A1 | ANTI-CARIES ORAL COMPOSITIONS | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286216-A1 | Surface Active Calcium Phosphates | ORAI1, CA2, CACNA2D3 | OTC 2609/4885DDAH1 347/4885NOS2 607/4885 |
| US-20250222111-A1 | DUAL-RATE RELEASE FORMULATION WITH HIGH DRUG LOADING | SLC7A1, SLC7A5, SLC43A1 | OTC 565/4885DDAH1 2384/4885NOS2 1987/4885 |
| US-20220111057-A1 | DUAL-RATE RELEASE FORMULATION WITH HIGH DRUG LOADING | SLC7A1, SLC7A5, SLC43A1 | OTC 565/4885DDAH1 2384/4885NOS2 1987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.